HCK and acute myeloid leukemia: Using SU6656, an inhibitor that—unlike many SFK inhibitors—does not affect FLT3-ITD, and specific RNA targeting, HCK was recently shown to be the STAT5 tyrosine kinase in the MV4-11 AML cell line [30].